DVx Past Earnings Performance
Past criteria checks 0/6
DVx's earnings have been declining at an average annual rate of -14.1%, while the Healthcare industry saw earnings growing at 6.4% annually. Revenues have been growing at an average rate of 2.4% per year. DVx's return on equity is 0.6%, and it has net margins of 0.1%.
Key information
-14.1%
Earnings growth rate
-13.8%
EPS growth rate
| Healthcare Industry Growth | 7.9% |
| Revenue growth rate | 2.4% |
| Return on equity | 0.6% |
| Net Margin | 0.1% |
| Next Earnings Update | 31 Jan 2025 |
Recent past performance updates
Revenue & Expenses Breakdown
How DVx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 47,252 | 54 | 4,173 | 0 |
| 30 Jun 24 | 46,602 | 127 | 4,091 | 0 |
| 31 Mar 24 | 45,851 | 172 | 3,964 | 0 |
| 31 Dec 23 | 46,191 | 398 | 3,978 | 0 |
| 30 Sep 23 | 46,497 | 753 | 3,966 | 0 |
| 30 Jun 23 | 47,314 | 918 | 3,966 | 0 |
| 31 Mar 23 | 47,483 | 936 | 3,990 | 0 |
| 31 Dec 22 | 47,030 | 866 | 3,986 | 0 |
| 30 Sep 22 | 47,082 | 920 | 3,961 | 0 |
| 30 Jun 22 | 46,426 | 855 | 3,938 | 0 |
| 31 Mar 22 | 45,496 | 863 | 3,925 | 0 |
| 31 Dec 21 | 44,522 | 823 | 3,893 | 0 |
| 30 Sep 21 | 43,729 | 769 | 3,905 | 0 |
| 30 Jun 21 | 43,227 | 740 | 3,903 | 0 |
| 31 Mar 21 | 41,007 | 572 | 3,909 | 0 |
| 31 Dec 20 | 41,634 | 643 | 4,020 | 0 |
| 30 Sep 20 | 41,842 | 640 | 4,071 | 0 |
| 30 Jun 20 | 42,412 | 675 | 4,151 | 0 |
| 31 Mar 20 | 44,653 | 792 | 4,250 | 0 |
| 31 Dec 19 | 43,896 | 944 | 4,300 | 0 |
| 30 Sep 19 | 42,751 | 900 | 4,252 | 0 |
| 30 Jun 19 | 41,232 | 845 | 4,225 | 0 |
| 31 Mar 19 | 40,380 | 974 | 4,161 | 0 |
| 31 Dec 18 | 39,513 | 744 | 4,024 | 0 |
| 30 Sep 18 | 39,133 | 780 | 4,009 | 0 |
| 30 Jun 18 | 38,565 | 720 | 3,965 | 0 |
| 31 Mar 18 | 38,275 | 856 | 3,970 | 0 |
| 31 Dec 17 | 37,989 | 944 | 3,926 | 0 |
| 30 Sep 17 | 37,026 | 1,030 | 3,851 | 0 |
| 30 Jun 17 | 36,473 | 1,162 | 3,792 | 0 |
| 31 Mar 17 | 35,266 | 1,025 | 3,687 | 0 |
| 31 Dec 16 | 34,812 | 1,076 | 3,577 | 0 |
| 30 Sep 16 | 33,751 | 1,046 | 3,507 | 0 |
| 30 Jun 16 | 32,549 | 1,003 | 3,448 | 0 |
| 31 Mar 16 | 31,372 | 1,289 | 3,404 | 0 |
| 31 Dec 15 | 29,900 | 1,221 | 3,463 | 0 |
| 30 Sep 15 | 29,196 | 1,159 | 3,475 | 0 |
| 30 Jun 15 | 28,899 | 1,217 | 3,435 | 0 |
| 31 Mar 15 | 28,647 | 919 | 3,376 | 0 |
| 31 Dec 14 | 28,358 | 845 | 3,467 | 0 |
| 30 Sep 14 | 27,939 | 825 | 3,436 | 0 |
| 30 Jun 14 | 27,298 | 788 | 3,377 | 0 |
| 31 Mar 14 | 26,420 | 788 | 3,279 | 0 |
| 31 Dec 13 | 25,177 | 764 | 3,144 | 0 |
Quality Earnings: 3079 has a large one-off loss of ¥296.0M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 3079's current net profit margins (0.1%) are lower than last year (1.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3079's earnings have declined by 14.1% per year over the past 5 years.
Accelerating Growth: 3079's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 3079 had negative earnings growth (-92.8%) over the past year, making it difficult to compare to the Healthcare industry average (10.6%).
Return on Equity
High ROE: 3079's Return on Equity (0.6%) is considered low.